PARK10 candidate RNF11 is expressed by vulnerable neurons and localizes to Lewy bodies in Parkinson disease brain

Journal of Neuropathology and Experimental Neurology

Volumn 66, Issue 10, 2007, Pages 955-964

  Anderson, Leah R ^a,b   Betarbet, Ranjita ^a   Gearing, Marla ^a   Gulcher, Jeffrey ^c   Hicks, Andrew A ^c   Stefánsson, Kári ^c   Lah, James J ^a   Levey, Allan I ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c DECODE GENETICS   (Iceland)

Author keywords

Lewy bodies; Neurodegeneration; Parkinson disease; Substantia nigra; Synuclein; Ubiquitin proteasome system

Indexed keywords

PROTEIN DERIVATIVE; RING FINGER PROTEIN 11; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BRAIN; BRAIN NERVE CELL; CONTROLLED STUDY; GENE LOCUS; HUMAN; HUMAN TISSUE; IDIOPATHIC DISEASE; IMMUNOHISTOCHEMISTRY; LEWY BODY; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SUBSTANTIA NIGRA;

AGED; AGED, 80 AND OVER; AMINO ACID SEQUENCE; ANIMALS; AUTOPSY; BLOTTING, NORTHERN; BRAIN CHEMISTRY; CARRIER PROTEINS; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; LEWY BODIES; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; NEURONS; PARAFFIN EMBEDDING; PARKINSON DISEASE; PLASMIDS; RATS;

EID: 34948881735     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/nen.0b013e3181567f17     Document Type: Article

References (50)

1. Hely MA, Morris JG, Reid WG, et al. Sydney Multicenter Study of Parkinson's disease: Non-L-dopa-responsive problems dominate at 15 years. Mov Disord 2005;20:190-99
2. Dawson TM, Dawson VL. Molecular pathways of neurodegeneration in Parkinson's disease. Science 2003;302:819-22
3. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 1997;276:2045-47
4. Kitada T, Asakawa S, Hattori N, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998;392:605-8
5. Leroy E, Boyer R, Auburger G, et al. The ubiquitin pathway in Parkinson's disease. Nature 1998;395:451-52
6. Bonifati V, Rizzu P, van Baren MJ, et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 2003;299:256-59
7. Valente EM, Abou-Sleiman PM, Caputo V, et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 2004;304:1158-60
8. Zimprich A, Biskup S, Leitner P, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004;44:601-7
9. Paisan-Ruiz C, Lang AE, Kawarai T, et al. LRRK2 gene in Parkinson disease: Mutation analysis and case control association study. Neurology 2005;65:696-700
10. Hicks AA, Petursson H, Jonsson T, et al. A susceptibility gene for late-onset idiopathic Parkinson's disease. Ann Neurol 2002;52:549-55
11. Li YJ, Scott WK, Hedges DJ, et al. Age at onset in two common neurodegenerative diseases is genetically controlled. Am J Hum Genet 2002;70:985-93
12. Oliveira SA, Li YJ, Noureddine MA, et al. Identification of risk and age-at-onset genes on chromosome 1p in Parkinson disease. Am J Hum Genet 2005;77:252-64
13. Maraganore DM, de Andrade M, Lesnick TG, et al. High-resolution whole-genome association study of Parkinson disease. Am J Hum Genet 2005;77:685-93
14. Noureddine MA, Li YJ, van der Walt JM, et al. Genomic convergence to identify candidate genes for Parkinson disease: SAGE analysis of the substantia nigra. Mov Disord 2005;20:1299-1309
15. Seki N, Hattori A, Hayashi A, et al. Cloning and expression profile of mouse and human genes, Rnf11/RNF11, encoding a novel RING-H2 finger protein. Biochim Biophys Acta 1999;1489:421-27
16. Moore DJ, West AB, Dawson VL, et al. Molecular pathophysiology of Parkinson's disease. Annu Rev Neurosci 2005;28:57-87
17. Joazeiro CA, Weissman AM. RING finger proteins: Mediators of ubiquitin ligase activity. Cell 2000;102:549-52
18. Forman MS, Trojanowski JQ, Lee VM. Neurodegenerative diseases: A decade of discoveries paves the way for therapeutic breakthroughs. Nat Med 2004;10:1055-63
19. Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991;41:479-86
20. 4 muscarinic acetylcholine receptor. J Neurosci 2002;22:9776-84
21. Zhang W, Basile AS, Gomeza J, et al. Characterization of central inhibitory muscarinic autoreceptors by the use of muscarinic acetylcholine receptor knock-out mice. J Neurosci 2002;22:1709-17
22. Duda JE, Giasson BI, Mabon ME, et al. Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases. Ann Neurol 2002;52:205-10
23. Ciliax BJ, Heilman C, Demchyshyn LL, et al. The dopamine transporter: Immunochemical characterization and localization in brain. J Neurosci 1995;15:1714-23
24. Levey AI, Armstrong DM, Atweh SF, et al. Monoclonal antibodies to choline acetyltransferase: Production, specificity, and immunohistochemistry. J Neurosci 1983;3:1-9
25. Miller GW, Gilmor ML, Levey AI. Generation of transporter-specific antibodies. Methods Enzymol 1998;296:407-22
26. Miller GW, Erickson JD, Perez JT, et al. Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson's disease. Exp Neurol 1999;156:138-48
27. Levey AI. Immunological localization of m1-m5 muscarinic acetylcholine receptors in peripheral tissues and brain. Life Sci 1993;52:441-48
28. 5 receptor immunolocalization in rat and monkey brain. Synapse 2000;37:125-45
29. Solano SM, Miller DW, Augood SJ, et al. Expression of α-synuclein, parkin, and ubiquitin carboxy-terminal hydrolase L1 mRNA in human brain: Genes associated with familial Parkinson's disease. Ann Neurol 2000;47:201-10
30. Irizarry MC, Growdon W, Gomez-Isla T, et al. Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain α-synuclein immunoreactivity. J Neuropathol Exp Neurol 1998;57:334-37
31. Doran JF, Jackson P, Kynoch PA, et al. Isolation of PGP 9.5, a new human neurone-specific protein detected by high-resolution two-dimensional electrophoresis. J Neurochem 1983;40:1542-47
32. Bandopadhyay R, Kingsbury AE, Cookson MR, et al. The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson's disease. Brain 2004;127:420-30
33. Goldberg MS, Pisani A, Haburcak M, et al. Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial Parkinsonism-linked gene DJ-1. Neuron 2005;45:489-96
34. Feany MB, Pallanck LJ. Parkin: A multipurpose neuroprotective agent? Neuron 2003;38:13-16
35. Sulzer D. α-Synuclein and cytosolic dopamine: Stabilizing a bad situation. Nat Med 2001;7:1280-82
36. Betarbet R, Sherer TB, MacKenzie G, et al. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 2000;3:1301-6
37. McNaught KS, Bjorklund LM, Belizaire R, et al. Proteasome inhibition causes nigral degeneration with inclusion bodies in rats. Neuroreport 2002;13:1437-41
38. McNaught KS, Perl DP, Brownell AL, et al. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann Neurol 2004;56:149-62
39. Spillantini MG, Schmidt ML, Lee VM, et al. α-Synuclein in Lewy bodies. Nature 1997;388:839-40
40. Shimura H, Hattori N, Kubo S, et al. Immunohistochemical and subcellular localization of Parkin protein: Absence of protein in autosomal recessive juvenile parkinsonism patients. Ann Neurol 1999;45:668-72
41. Bandopadhyay R, Kingsbury AE, Muqit MM, et al. Synphilin-1 and parkin show overlapping expression patterns in human brain and form aggresomes in response to proteasomal inhibition. Neurobiol Dis 2005;20:401-11
42. Wakabayashi K, Engelender S, Yoshimoto M, et al. Synphilin-1 is present in Lewy bodies in Parkinson's disease. Ann Neurol 2000;47:521-23
43. Schlossmacher MG, Frosch MP, Gai WP, et al. Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies. Am J Pathol 2002;160:1655-67
44. Lowe J, McDermott H, Landon M, et al. Ubiquitin carboxyl-terminal hydrolase (PGP 9.5) is selectively present in ubiquitinated inclusion bodies characteristic of human neurodegenerative diseases. J Pathol 1990;161:153-60
45. Pawlyk AC, Giasson BI, Sampathu DM, et al. Novel monoclonal antibodies demonstrate biochemical variation of brain parkin with age. J Biol Chem 2003;278:48120-28
46. Spillantini MG, Crowther RA, Jakes R, et al. α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci USA 1998;95:6469-73
47. McNaught KS, Mytilineou C, Jnobaptiste R, et al. Impairment of the ubiquitin-proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures. J Neurochem 2002;81:301-6
48. Li H, Seth A. An RNF11: Smurf2 complex mediates ubiquitination of the AMSH protein. Oncogene 2004;23:1801-8
49. Kitching R, Wong MJ, Koehler D, et al. The RING-H2 protein RNF11 is differentially expressed in breast tumours and interacts with HECT-type E3 ligases. Biochim Biophys Acta 2003;1639:104-12
50. Subramaniam V, Li H, Wong M, et al. The RING-H2 protein RNF11 is overexpressed in breast cancer and is a target of Smurf2 E3 ligase. Br J Cancer 2003;89:1538-44